Mouse/rat Amyloid-beta (1-42) ELISA
- Regulatory Status
- RUO
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 1 x 18h, 1 x 1h, 1 x 30 min.
- Standard range
- 1.56 - 100 pg/mL
- Specimen / Volumes
- 100 µL serum, EDTA-plasma
- Substrate / isotope
- TMB 450 nm
This kit was previously sold as JP27721 Mouse/rat Amyloid-beta (1-42) ELISA.
This ELISA measures endogenous rat/mouse Amyloid-β (1-42). The plaques which appear in the brains of Alzheimer's disease patients are mostly constituted by the Amyloidβ protein (Aβ). Aβ is a peptide which consists of 40 or 42 (43) amino acids, and reports show that this is cleaved from β- and γ- secretase from the amyloid precursor protein (APP). Reports have shown many variants of Aβ exist and are clarified into the culture supernatant from the APP cDNA transfected mouse neuroblastoma cell. Furthermore, in 1995, a dominant and differential deposition of distinct β amyloid peptide species, Aβ (N3pE), in senile plaques was found by Saido et al. This modified molecule, starting at the 3rd amino terminal residue, glutamate, was discovered to convert to pyroglutamate through intramolecular dehydration.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.